Fluvoxamine Efficacy and Management in OCD Treatment

Introduction to Fluvoxamine

The American Academy of Child and Adolescent Psychiatry recommends fluvoxamine as a treatment option for OCD, with a number needed to treat (NNT) of 5, compared to NNT of 3 for cognitive-behavioral therapy with exposure and response prevention (ERP) 1

SSRIs, including fluvoxamine, have a number needed to treat (NNT) of 5 for OCD, compared to NNT of 3 for cognitive-behavioral therapy with exposure and response prevention (ERP), according to the American Academy of Child and Adolescent Psychiatry 1

The American Academy of Child and Adolescent Psychiatry suggests that fluvoxamine requires 8-12 weeks at maximum tolerated dose to fully assess efficacy, with clinically significant improvement typically by week 6 2, 1

Cognitive-behavioral therapy with ERP is the psychological treatment of choice and should be offered alongside or instead of medication, with 10-20 sessions recommended, according to the National Institute of Mental Health and the American Psychological Association 3, 4, 1
Patient adherence to between-session ERP homework is the strongest predictor of good outcomes, as reported by the American Psychological Association 4, 1
CBT has larger effect sizes than pharmacotherapy alone (NNT 3 vs 5), making combined treatment optimal, according to the American Academy of Child and Adolescent Psychiatry 1

Common adverse effects of fluvoxamine include nausea, somnolence, headache, dry mouth, and insomnia, with a boxed warning for suicidal ideation through age 24, according to the Journal of the American Academy of Child and Adolescent Psychiatry 2

If inadequate response after 12 weeks at maximum dose, consider augmentation with aripiprazole, particularly if comorbid bipolar features, as suggested by the American Academy of Child and Adolescent Psychiatry 4
Glutamatergic agents have evidence for augmentation in treatment-resistant OCD, according to the American Academy of Child and Adolescent Psychiatry 4

Do not discontinue fluvoxamine prematurely—maintain treatment for minimum 8-12 weeks before declaring treatment failure, as recommended by the American Academy of Child and Adolescent Psychiatry 1
Monitor closely for behavioral activation, akathisia, or suicidal ideation in the first weeks of treatment, according to the Journal of the American Academy of Child and Adolescent Psychiatry and the American Academy of Child and Adolescent Psychiatry 2, 1

Maintenance therapy with fluvoxamine reduces relapse risk in up to 67% of OCD patients, and most patients require 12-24 months of maintenance therapy after achieving remission, as reported by the American Academy of Child and Adolescent Psychiatry 4, 1
Address family accommodation behaviors through psychoeducation, as these maintain OCD symptoms, according to the National Institute of Mental Health and the American Psychological Association 3, 4